Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing
Saravana P. Selvanathan, Garrett T. Graham, Hayriye V. Erkizan, et al.
Proceedings of the National Academy of Sciences (2015) Vol. 112, Iss. 11
Open Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

RNA-Binding Proteins in Cancer: Old Players and New Actors
Bruno Pereira, Marc Billaud, Raquel Almeida
Trends in cancer (2017) Vol. 3, Iss. 7, pp. 506-528
Closed Access | Times Cited: 663
EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma
Aparna Gorthi, July Carolina Romero, Eva Loranc, et al.
Nature (2018) Vol. 555, Iss. 7696, pp. 387-391
Open Access | Times Cited: 280
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram, Matthew T. Chang, Philip Jonsson, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 12, pp. 735-748
Open Access | Times Cited: 272
Ewing’s Sarcoma
Nicolò Riggi, Mario L. Suvà, Ivan Stamenkovic
New England Journal of Medicine (2021) Vol. 384, Iss. 2, pp. 154-164
Open Access | Times Cited: 235
RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment
Suntaek Hong
Journal of Cancer Prevention (2017) Vol. 22, Iss. 4, pp. 203-210
Open Access | Times Cited: 135
Enhanced construction of gene regulatory networks using hub gene information
Donghyeon Yu, Johan Lim, Xinlei Wang, et al.
BMC Bioinformatics (2017) Vol. 18, Iss. 1
Open Access | Times Cited: 112
Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Kalliopi Tsafou, Purushottam B. Tiwari, Julie D. Forman‐Kay, et al.
Journal of Molecular Biology (2018) Vol. 430, Iss. 16, pp. 2321-2341
Closed Access | Times Cited: 98
Biomolecular condensates in neurodegeneration and cancer
Stephanie Spannl, Maria Tereshchenko, Giovanni J. Mastromarco, et al.
Traffic (2019) Vol. 20, Iss. 12, pp. 890-911
Open Access | Times Cited: 98
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model
Tsion Z. Minas, Didier Surdez, Tahereh Javaheri, et al.
Oncotarget (2016) Vol. 8, Iss. 21, pp. 34141-34163
Open Access | Times Cited: 89
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou, Libin Zou, Hangyu Liao, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 2, pp. 692-707
Open Access | Times Cited: 72
Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation
Martin F. Orth, Didier Surdez, Tobias Faehling, et al.
Cell Reports (2022) Vol. 41, Iss. 10, pp. 111761-111761
Open Access | Times Cited: 40
Discovery of Small Molecules that Inhibit the Disordered Protein, p27Kip1
Luigi I. Iconaru, David Ban, Kavitha Bharatham, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 77
Targeting RNA helicases in cancer: The translation trap
Marise R. Heerma van Voss, P. J. van Diest, Venu Raman
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2017) Vol. 1868, Iss. 2, pp. 510-520
Open Access | Times Cited: 75
Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets
Twana M. Jackson, Mark Bittman, Linda Granowetter
Current problems in pediatric and adolescent health care (2016) Vol. 46, Iss. 7, pp. 213-228
Closed Access | Times Cited: 73
CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing’s sarcoma
Nathan T. Ross, Felix Lohmann, Seth Carbonneau, et al.
Nature Chemical Biology (2019) Vol. 16, Iss. 1, pp. 50-59
Open Access | Times Cited: 72
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting
Emily R. Theisen, Kathleen I. Pishas, Ranajeet S. Saund, et al.
Oncotarget (2016) Vol. 7, Iss. 14, pp. 17616-17630
Open Access | Times Cited: 64
Telomere-related Markers for Cancer
Xiaotian Yuan, Mingkai Dai, Dawei Xu
Current Topics in Medicinal Chemistry (2020) Vol. 20, Iss. 6, pp. 410-432
Open Access | Times Cited: 56
The Crosstalk Between Epigenetic Mechanisms and Alternative RNA Processing Regulation
Jian Zhang, Yizhe Zhang, Jing Jiang, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 54
TK216 targets microtubules in Ewing sarcoma cells
Juan Manuel Povedano, Vicky Li, Katherine E. Lake, et al.
Cell chemical biology (2022) Vol. 29, Iss. 8, pp. 1325-1332.e4
Open Access | Times Cited: 33
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Paul A. Meyers, Noah Federman, Najat C. Daw, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3725-3734
Closed Access | Times Cited: 7
Sequence-specific targeting of intrinsically disordered protein regions
Kejia Wu, Hanlun Jiang, Derrick R. Hicks, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes
Laurens G.L. Sand, Károly Szuhai, Pancras C.W. Hogendoorn
International Journal of Molecular Sciences (2015) Vol. 16, Iss. 7, pp. 16176-16215
Open Access | Times Cited: 64
Inhibition of the oncogenic fusion protein EWS-FLI1 causes G 2 -M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma
Stefan Zöllner, Saravana P. Selvanathan, Garrett T. Graham, et al.
Science Signaling (2017) Vol. 10, Iss. 499
Open Access | Times Cited: 57
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Y. Chung, Eugenio Gaudio, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 16, pp. 5167-5176
Open Access | Times Cited: 54
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma
Tim Hensel, Chiara Giorgi, Oxana Schmidt, et al.
Oncotarget (2015) Vol. 7, Iss. 2, pp. 1451-1463
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top